- This event has passed.
Directors Career Symposium May 30, 2019
May 30 @ 1:00 pm - 4:30 pm
Directors Career Symposium will take place May 30, 2019.
Join us for the annual Integrated Training in Cancer Model Systems Director’s Career Symposium, moderated by Hector Franco, PhD, and featuring career focused talks representing three different career paths: Research, Medicine, and Publishing.
In addition to a full afternoon of career talks, we will be offering concurrent breakout sessions with each invited speaker for trainees who are interested in learning more about a particular career path. If you are interested in a more in-depth discussion with one of the speakers you will have the opportunity to select that breakout session when registering. Snacks will be served at the breakout sessions. Please watch this site for upcoming details.Register Now
|12:00 – 1:00 pm||Lunch for attendees||UNC Lineberger 00-002 Pagano Conference Room|
|1:00 – 3:15 pm|| Career Symposium main session
1:00 pm Christine (Tina) Ardito-Abraham, PhD
1:35 pm Harmony Turk, PhD
2:10 pm Dominico Vigil, PhD
|Pagano Conference Room|
|3:30 – 4:30pm||Breakout Sessions
Pagano Conference Room
UNC Lineberger 12-001
UNC Lineberger 32-001
Christine Ardito-Abraham, PhD, Regional Medical Liason, Amgen Inc.
Dr. Ardito-Abraham is a Regional Medical Liaison at Amgen, an American multinational biopharmeceutical company that uses cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies. As an experienced basic scientist with clinical research experience, her goal is to serve as a reliable, informative liaison for the scientific and medical communities to help discover, direct and deliver promising therapeutics to her patients. Her area of expertise is oncology with a special interest in pancreatic cancer. Dr. Ardito-Abraham received her PhD from Stony Brook University, where she studied the ADAM10/Notch and ADAM17/EGFR signaling pathways in pancreatic cancer. She then completed her postdoctoral research, initially at the Hospital for Special Surgery with Dr. Carl Blobel investigating the roles of ADAM10 and Notch signaling in tumor angiogenesis, then later at Cold Spring Harbor Laboratory with Dr. David Tuveson, where she developed novel methods to investigate the vasculature of pancreatic cancer. After her postdoctoral studies, she served as Research Program Manager at the Lustgarten Foundation.
Harmony Turk, PhD, Scientific Editor, Cell Press (Cancer Cell)
Dr. Turk is a Scientific Editor at Cancer Cell, which provides a high-profile forum for publication of major advances into answering important questions relevant to naturally occurring cancers. Her primary role at the journal is to recruit scientific publications, to evaluate the suitability of submitted manuscripts for Cancer Cell, and to guide the review, revision, and publication process. Dr. Turk received her bachelor’s and PhD degrees at Texas A&M, where she studied EGFR signaling in lipid rafts in colorectal cancer under the mentorship of Dr. Robert Chapkin. She then conducted her postdoctoral research with Dr. Jacques Ghysdael at the Institut Curie, where she studied microenvironment-mediated Wnt signaling in T cell acute lymphoblastic leukemia.
Dominico Vigil, PhD, Principal Scientist, Kymera Therapeutics
Dr. Vigil is a Principal Scientist at Kymera Therapeutics, a biotechnology company that uses a small molecule-based knockdown strategy to rationally design and develop heterobifunctional molecules that recruit intractable disease-causing proteins to E3 ubiquitin ligases, resulting in the protein’s ubiquitination and subsequent degradation. As a biology team lead and early target champion, he together with chemists and pharmacologists develops heterobifunctional degraders against key oncoproteins as potential novel first-in-class therapeutics, and explores early target space in signaling, apoptosis, and immuno-oncology to determine which targets will be ideal for targeted protein degradation. Dr. Vigil received his PhD degree at the University of California, San Diego, where he studied protein kinase A. He then conducted his postdoctoral studies, initially at the University of North Carolina at Chapel Hill with Drs. Sharon Campbell and Channing Der where he studied guanine nucleotide exchange factors for small GTPases, then later at Vanderbilt University with Dr. Stephen Fesik, where he applied fragment-based methods and structure-based design to develop inhibitors of MCL-1.